Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Monte Rosa Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Zentalis Pharmaceuticals Inc. June 16, 202671.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Zentalis Pharmaceuticals Inc. | Grant or award | +57,100 | — | — |
| Jun 17, 2025 | Zentalis Pharmaceuticals Inc. | Grant or award | +57,603 | — | — |
| Jan 31, 2025 | Zentalis Pharmaceuticals Inc. | Open-market purchase | +60,000 | $1.72 | $103,200 |
| Jun 21, 2024 | Zentalis Pharmaceuticals Inc. | Grant or award | +41,581 | — | — |
| Sep 11, 2023 | Zentalis Pharmaceuticals Inc. | Open-market sale | −5,000 | $25.05 | $125,250 |
| Jun 16, 2023 | Zentalis Pharmaceuticals Inc. | Grant or award | +16,364 | — | — |
Questions about Jan Skvarka
What boards is Jan Skvarka on?
Jan Skvarka sits on the boards of Monte Rosa Therapeutics Inc. and Zentalis Pharmaceuticals Inc.
How long has Jan Skvarka served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.